[go: up one dir, main page]

IN2014CN03307A - - Google Patents

Info

Publication number
IN2014CN03307A
IN2014CN03307A IN3307CHN2014A IN2014CN03307A IN 2014CN03307 A IN2014CN03307 A IN 2014CN03307A IN 3307CHN2014 A IN3307CHN2014 A IN 3307CHN2014A IN 2014CN03307 A IN2014CN03307 A IN 2014CN03307A
Authority
IN
India
Prior art keywords
methylene
formula
carbolactones
pregn
endometriosis
Prior art date
Application number
Inventor
Jan Hübner
Rolf Bohlmann
Isabella Gashaw
Oliver Martin Fischer
Joachim Kuhnke
Norbert Gallus
Ildiko Terebesi
Reinhard Nubbemeyer
Original Assignee
Bayer Pharma AG
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2011/069464 external-priority patent/WO2012059594A1/en
Application filed by Bayer Pharma AG, Bayer Ip Gmbh filed Critical Bayer Pharma AG
Publication of IN2014CN03307A publication Critical patent/IN2014CN03307A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/007—3 membered carbocyclic rings in position 6-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to 18 methyl 6 7 methylene 17 pregn 4 ene 21 17ß carbolactones of the general formula (I) where the 6 7 methylene group may be in the a or ß position to pharmaceutical preparations comprising at least one isomer of the formula (I) and to the use thereof in the treatment of endometriosis.
IN3307CHN2014 2011-11-04 2012-11-02 IN2014CN03307A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2011/069464 WO2012059594A1 (en) 2010-11-04 2011-11-04 Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
DE102012212838 2012-07-23
PCT/EP2012/071700 WO2013064620A1 (en) 2011-11-04 2012-11-02 18-methyl-6,7-methylene-3-oxo-17-pregn-4-ene-21,17β-carbolactones, pharmaceutical preparations comprising said compounds and use thereof in the treatment of endometriosis

Publications (1)

Publication Number Publication Date
IN2014CN03307A true IN2014CN03307A (en) 2015-07-03

Family

ID=48191408

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3307CHN2014 IN2014CN03307A (en) 2011-11-04 2012-11-02

Country Status (15)

Country Link
US (1) US20140288035A1 (en)
JP (1) JP2014532685A (en)
KR (1) KR20140088197A (en)
CN (1) CN103957921A (en)
AR (1) AR088622A1 (en)
AU (1) AU2012331089A1 (en)
BR (1) BR112014010590A2 (en)
CA (1) CA2854215A1 (en)
EA (1) EA201400537A1 (en)
HK (1) HK1199712A1 (en)
IL (1) IL232325A0 (en)
IN (1) IN2014CN03307A (en)
MX (1) MX2014005367A (en)
TW (1) TW201322986A (en)
WO (1) WO2013064620A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2885523T3 (en) 2011-11-23 2021-12-14 Therapeuticsmd Inc Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (en) 2014-05-22 2016-10-12 Therapeuticsmd Inc PHARMACEUTICAL COMPOSITION OF ESTRADIOL AND PROGESTERONE FOR HORMONAL REPLACEMENT THERAPY
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CN117417303B (en) * 2023-10-19 2024-07-09 黑龙江中医药大学 Medicine for treating endometriosis and preparation method thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1183500B (en) 1962-10-12 1964-12-17 Schering Ag Process for the production of alpha, beta-methylene ketones of the steroid series
FR1529949A (en) 1966-05-19 1968-06-21 American Home Prod Steroid compounds such as 10-methylgon-4-en-3-ones and their derivatives
DE1921396C3 (en) 1969-04-23 1978-04-27 Schering Ag, 1000 Berlin Und 4619 Bergkamen 17 a-Hydroperoxy-16 a, 18-dimethyl-20ketosteroids, process for the preparation of the same, and other corresponding intermediates
DE2922500A1 (en) 1979-05-31 1980-12-04 Schering Ag 6 BETA. 7 BETA
DE19633685C1 (en) * 1996-08-12 1997-10-09 Schering Ag Production of drospirenone useful as steroidal agent
RU2275198C2 (en) 2000-01-18 2006-04-27 Шеринг Акциенгезелльшафт Drospyrenon for replacement hormonotherapy
CL2004000574A1 (en) * 2003-03-21 2005-02-11 Pharmacia Corp Sa Organizada B PROCESS TO PREPARE A 17-ESPIROLACTONE COMPOUND OR OPEN LACTONE SALT BY CARBONILATION OF THE CORRESPONDING 17-ALQUENIL OR DERIVED ALQUINIL, THE INTERMEDIARIES USED AND ITS OBTAINING PROCESS.
DE102007011105A1 (en) 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid receptor antagonist for producing drug for permanent treatment of endometriosis, comprises spironolactone, eplerenone and drospirenone
WO2012059594A1 (en) * 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity

Also Published As

Publication number Publication date
KR20140088197A (en) 2014-07-09
MX2014005367A (en) 2014-07-09
AU2012331089A1 (en) 2014-05-22
EA201400537A1 (en) 2014-10-30
CN103957921A (en) 2014-07-30
US20140288035A1 (en) 2014-09-25
HK1199712A1 (en) 2015-07-17
BR112014010590A2 (en) 2017-05-02
JP2014532685A (en) 2014-12-08
IL232325A0 (en) 2014-06-30
TW201322986A (en) 2013-06-16
WO2013064620A1 (en) 2013-05-10
AR088622A1 (en) 2014-06-25
CA2854215A1 (en) 2013-05-10

Similar Documents

Publication Publication Date Title
IN2014CN03307A (en)
IN2014DN10670A (en)
PH12014502397B1 (en) Pesticidal compositions and processes related thereto
PT2766380T (en) 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MX2016001037A (en) Inhibitors of transcription factors and uses thereof.
IN2015DN01156A (en)
HK1216176A1 (en) Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
SI3378862T1 (en) Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of multiple sclerosis
IN2014MN02652A (en)
PH12013502686A1 (en) Pesticidal compositions and processes related thereto
BR112015000561A2 (en) irak inhibitors and uses thereof
EA019744B9 (en) Isothiazolyloxyphenyl amidines and use thereof for combating fungi and seed material treated with isothiazolyloxyphenyl amidines
UA114656C2 (en) Novel pyridine derivatives
PH12013500467A1 (en) Pharmaceutical composition
BR112013016862A2 (en) combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
IL224544B (en) Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
LT2739615T (en) Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
EP2796461A4 (en) PROCESSES FOR THE PREPARATION OF ICOTINIB AND ICOTINIB HYDROCHLORIDE AND INTERMEDIATES THEREOF
MY162397A (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
MX348726B (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation.
UA107550C2 (en) ESTRA-1,3,5 (10), 16-TETRAEIN-3-CARBOXAMAMID DERIVATIVES, THE METHODS OF THEIR PREPARATION, THE PHARMACEUTICAL PREPARATIONS THEREOF, AND THEIR USE
WO2011150190A3 (en) Hcv inhibitor compounds and methods of use thereof
GB2497453B8 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
SG10201900541QA (en) Derivatives of xanthone compounds